L3VLUP
ProSign in

ZBH · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ZBHVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ZBH
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterZBHVRTX
Q3 202021 holders, $5.3bn31 holders, $21.9bn
Q4 202022 holders, $6.0bn30 holders, $18.4bn
Q1 202122 holders, $5.5bn31 holders, $15.4bn
Q2 202123 holders, $5.6bn30 holders, $12.7bn
Q3 202123 holders, $4.4bn35 holders, $10.1bn
Q4 202120 holders, $3.4bn28 holders, $12.4bn
Q1 202217 holders, $3.4bn23 holders, $16.1bn
Q2 202216 holders, $3.1bn25 holders, $18.1bn
Q3 202219 holders, $3.7bn22 holders, $18.4bn
Q4 202220 holders, $4.6bn28 holders, $18.4bn
Q1 202326 holders, $4.7bn26 holders, $21.4bn
Q2 202323 holders, $5.1bn27 holders, $24.7bn
Q3 202327 holders, $4.0bn33 holders, $24.3bn
Q4 202321 holders, $4.3bn32 holders, $28.6bn
Q1 202419 holders, $5.7bn31 holders, $29.8bn
Q2 202417 holders, $4.5bn29 holders, $33.4bn
Q3 202415 holders, $4.3bn27 holders, $33.5bn
Q4 202417 holders, $4.8bn26 holders, $28.5bn
Q1 202517 holders, $5.1bn21 holders, $35.4bn
Q2 202512 holders, $4.5bn21 holders, $32.3bn
Q3 202512 holders, $4.9bn22 holders, $25.9bn
Q4 20258 holders, $4.9bn26 holders, $31.8bn
Q1 20268 holders, $4.2bn25 holders, $31.8bn
Q2 202612 holders, $4.3bn26 holders, $34.6bn
ZBH

Zimmer Biomet Holdings Inc

Holders
17
Reported value
$4.8bn
Buyers
9
Sellers
6

Breadth +3 among 94 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$28.5bn
Buyers
14
Sellers
13

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 35 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ZBH (9)

Arrowstreet Capital LP, Bridgewater Associates LP, Citadel Advisors LLC, Dodge & Cox, First Eagle Investment Management LLC, Freestone Grove Partners LP, GAMCO Investors Inc, Holocene Advisors LP, Moore Capital Management LP

Only VRTX (18)

AllianceBernstein LP, ARK Investment Management LLC, Artisan Partners LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., Fidelity (FMR LLC), Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Millennium Management LLC, PDT Partners LLC, Renaissance Technologies LLC, Voloridge Investment Management LLC, Wellington Management Group LLP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →